Perspective Therapeutics, Inc. $CATX Shares Purchased by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC lifted its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 954.9% in the 1st quarter, Holdings Channel.com reports. The firm owned 3,164,582 shares of the company’s stock after purchasing an additional 2,864,582 shares during the quarter. Affinity Asset Advisors LLC’s holdings in Perspective Therapeutics were worth $13,196,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. AXQ Capital LP boosted its holdings in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Perspective Therapeutics by 6.1% in the fourth quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock valued at $149,000 after acquiring an additional 3,119 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in shares of Perspective Therapeutics by 25.0% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $69,000 after acquiring an additional 5,000 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the last quarter. Finally, Taylor & Morgan Wealth Management LLC increased its position in shares of Perspective Therapeutics by 6.6% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock worth $267,000 after purchasing an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Down 1.4%

Shares of CATX stock opened at $2.91 on Friday. The firm’s 50-day moving average is $3.31 and its two-hundred day moving average is $3.90. Perspective Therapeutics, Inc. has a 12 month low of $1.96 and a 12 month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. As a group, equities analysts predict that Perspective Therapeutics, Inc. will post -1.1 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on CATX shares. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a report on Friday. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $12.62.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.